BETHESDA, Md., March 15, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted ...
BETHESDA, Md., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of ...
The study also clarifies the functional role of the receptor's conserved sodium-binding pocket, showing that sodium egress strongly promotes activation-related conformational states, including a ...
NATICK, Mass.--(BUSINESS WIRE)--PIC Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-mechanism, first-in-class allosteric small molecule therapies ...
In this Innovation Spotlight, Gene Mack, the chief executive officer of Gain Therapeutics, discusses the company’s Magellan™ platform, which uss machine learning and structural modeling to identify ...
Designing proteins that can change their structure, and ultimately function, in response to specific molecular signals, a phenomenon known as allosteric regulation, has been a long-standing goal of ...
Atavistik Bio has launched with $60 million in series A financing to develop small-molecule drugs for metabolic diseases and cancer. The start-up is based on the work of Jared Rutter, a biochemist at ...
Cancer is one of the leading causes of death worldwide, affecting over 20 million individuals and killing 9.7 million in 2022 alone. Each of ~200 cancer types (and multiple subtypes) presents an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results